NeXtGen Biologics, INC filed a Form D with the Securities and Exchange Commission on 2025-09-22.
NeXtGen Biologics, INC filed a Form D notice of an exempt securities offering with the SEC on September 22, 2025. The filing reports $130K sold. Its industry group is Biotechnology. It names Jamie Grooms (Director), Jonelle Toothman (Executive Officer, Director), Gerald Kluft (Director) (SEC Form D, September 22, 2025).
Is this your company?
Sell to companies like NeXtGen Biologics, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-09-22 · the record
Pitching, partnering or investing alongside them? See who really runs and owns NeXtGen Biologics, INC.
Free to see. No signup.
More on the people and the money behind NeXtGen Biologics, INC, from the filings we hold.
Biotechnology raises by companies based in Florida, filed in September 2025, largest first.
Get an email when NeXtGen Biologics, INC files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when NeXtGen Biologics, INC raises, hires or launches. No email unless you switch it on.
Watch NeXtGen Biologics, INC →Get the full cited report on NeXtGen Biologics, INC
What the filing shows about NeXtGen Biologics, INC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on NeXtGen Biologics, INC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives NeXtGen Biologics, INC's address as 13800 Tech City Circle, Suite 200, Alachua, FL 32615.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
NeXtGen Biologics, INC is a registered filer with the SEC (CIK 1620524) and has filed since 2025-09-22. 1 filing is on record, the latest on 2025-09-22.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
NeXtGen Biologics, INC's Form D of 2025-09-22 names Jamie Grooms, Jonelle Toothman, Gerald Kluft and 4 more as its officers, directors or promoters.
Its new offerings report $130K sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Jamie Grooms is named as Director on the Form D that NeXtGen Biologics, INC filed with the SEC on 22 September 2025, one of 7 people that filing names.
Jonelle Toothman is named as Executive Officer and Director on the Form D that NeXtGen Biologics, INC filed with the SEC on 22 September 2025, one of 7 people that filing names.
Gerald Kluft is named as Director on the Form D that NeXtGen Biologics, INC filed with the SEC on 22 September 2025, one of 7 people that filing names.
Dan Hamister is named as Director on the Form D that NeXtGen Biologics, INC filed with the SEC on 22 September 2025, one of 7 people that filing names.
Elad Levy is named as Director on the Form D that NeXtGen Biologics, INC filed with the SEC on 22 September 2025, one of 7 people that filing names.
Brian Lipke is named as Director on the Form D that NeXtGen Biologics, INC filed with the SEC on 22 September 2025, one of 7 people that filing names.
Rick Wassel is named as Director on the Form D that NeXtGen Biologics, INC filed with the SEC on 22 September 2025, one of 7 people that filing names.
7 people named on the filing — 1 holding an executive role and 6 as directors only.
Named as of the 2025-09-22 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about NeXtGen Biologics, INC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on NeXtGen Biologics, INC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NeXtGen Biologics, INC covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist NeXtGen Biologics, INCYou get an alert in MentionFox the next time this company shows up.
If you're behind NeXtGen Biologics, INC: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for NeXtGen Biologics, INC. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/nextgen-biologics-inc-form-d-25000001